The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
about
Follicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal ModelsChemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulationPrioritizing genes of potential relevance to diseases affected by sex hormones: an example of myasthenia gravisThymic alterations in GM2 gangliosidoses model mice.C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravisCXCL13 antibody for the treatment of autoimmune disorders.Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.Impaired Cell Cycle Regulation in a Natural Equine Model of Asthma.Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia.Myasthenia gravis thymus: complement vulnerability of epithelial and myoid cells, complement attack on them, and correlations with autoantibody status.Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Blood Transcriptome Profiling in Myasthenia Gravis Patients to Assess Disease Activity: A Pilot RNA-seq StudyEndometrial CXCL13 expression is cycle regulated in humans and aberrantly expressed in humans and Rhesus macaques with endometriosis.Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.Tertiary lymphoid structures are confined to patients presenting with unifocal Langerhans Cell HistiocytosisCXCL13 is elevated in Sjögren's syndrome in mice and humans and is implicated in disease pathogenesisResearch advancement in immunopathogenesis of myasthenia gravis.Thymic remodeling associated with hyperplasia in myasthenia gravis.The thymus in myasthenia gravis: Site of "innate autoimmunity"?Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17.Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease.Human T follicular helper (Tfh) cells and disease.Idiopathic pulmonary fibrosis and a role for autoimmunity.Follicular helper T cell in immunity and autoimmunityReview on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.Granzyme B: evidence for a role in the origin of myasthenia gravis.B-cell-activating factor and autoimmune myasthenia gravis.Balance between Estrogens and Proinflammatory Cytokines Regulates Chemokine Production Involved in Thymic Germinal Center Formation.The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt SignalingUse of Toll-Like Receptor Agonists to Induce Ectopic Lymphoid Structures in Myasthenia Gravis Mouse Models.Clonal relationship between infiltrating immunoglobulin G4 (IgG4)-positive plasma cells in lacrimal glands and circulating IgG4-positive lymphocytes in Mikulicz's disease.Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis.Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.Myasthenia gravis associated with lupus nephritis.Thymus involvement in early-onset myasthenia gravis.Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC
P2860
Q26795577-36943A61-44D1-4A56-B88B-7394A7CC5219Q28585797-BD858C4B-F77F-4382-AAF1-8E3E0E8F2132Q30484806-2E0951CF-61FB-4132-B4B7-1E5D5F8D5581Q33697973-5E8F8ABE-15DF-40F4-9266-0274329CC46FQ33901646-BAED8B0A-A1FE-4F3B-8013-944AC2B5A79BQ34240032-511946D8-DA13-44E0-BC54-45224053BE70Q34504952-FCDEB06C-E06C-4EDC-8BA7-4281E06A0A2FQ35021391-C5845E47-1428-40C8-B96D-D692FCD3BE29Q35086918-9F8269F0-A93E-4D9A-A354-FCB60429A884Q35434799-86303C06-1EC5-4B04-A51B-F741294EB1B9Q35751484-D06F3DC6-56F3-4A4E-890C-A65CAA8D85D0Q35842700-6AA928F4-5A54-434A-AEF4-7E59931B87B2Q35963139-0344AA10-56CA-4656-B3D8-7A0C6A59F706Q36484383-FE068532-85AC-47D2-88A9-B2F100426E80Q36614763-F3AB9252-5C6C-4058-BA98-6FB4E0B47556Q36742625-067250EA-453D-4F57-8F41-BAB9669E9313Q36946564-69297925-482C-4528-B204-D2C38BECC037Q37224600-C1092404-50A0-4D7D-A3E4-ED3E961A1AD7Q37238275-3C8D85B6-1949-4199-A676-C760760D7F05Q37681317-405CD27D-2BD2-4FC8-8F10-6826C4B4CAA1Q37733580-A8194212-A3E1-4DB5-9E63-CE6809B89FC6Q37933171-F8A2D767-1BF6-4768-9ABE-4AE43D1E6944Q38068533-800D7D54-F550-4228-9A06-148BF6D0E990Q38091729-981C071B-91CD-4099-BBD7-9EFDB53A2996Q38154471-486A97EE-405C-4526-8B12-93A437CE0865Q38737879-0F5195AE-7E70-440D-894F-D64CC543DFB7Q38812644-DDF8F991-CAE6-4D1E-A312-87AF932C3E44Q38840238-54870099-F790-4AC6-8D0E-6C8F17426F4DQ38858288-798762DA-A9C3-48C3-8C2B-DB94B11528DAQ39954776-9F897972-FF35-4A56-8376-6EED056D78A2Q40179681-E02995BB-087A-4A33-8774-54AF4063C132Q41368509-8CD011E4-68CD-43B2-91EB-0CB5ADF82DF8Q41573243-E6B32D0C-D313-4634-A2FE-5616712585CCQ41848000-864982CF-6367-4872-BF2E-540A38956F3DQ42652389-703FD503-4FD7-469A-B1B0-CEFBF571AE5CQ44316843-8F134D99-45C9-43C7-9E7C-52CAC853DBD1Q45344123-740B35AF-408B-4E3B-9036-24A792F3F86CQ46404844-BAA261BA-559D-4C01-AC2B-1CBAE76D8C0AQ47846806-50F0DB08-81F5-49F5-96D5-70500050D440Q57251009-1D328509-EFDA-4D15-8147-6B6EFC792DFC
P2860
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@ast
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en-gb
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@nl
type
label
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@ast
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en-gb
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@nl
prefLabel
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@ast
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en-gb
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
@en
P2093
Amel Meraouna
Chantal Tallaksen
Frederique Truffault
Geraldine Cizeron-Clairac
P2860
P304
P3181
P356
10.1182/BLOOD-2005-06-2383
P407
P577
2006-07-15T00:00:00Z